Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Myocardial Infarction Market?

The market size for myocardial infarction has seen significant growth recently. The industry is set to expand from a value of $2.05 billion in 2024 to $2.2 billion in 2025, which reflects a compound annual growth rate (CAGR) of 7.2%. This historic growth can be credited to the advent of beta-blockers, the foundation of chest pain institutions, thrombolytic treatment methods, personalized healthcare techniques, and wearable heart-related devices.

What Growth Rate Is Forecasted for the Myocardial Infarction Market by 2029?

In the coming years, the myocardial infarction market is poised for impressive growth, which is projected to reach $2.94 billion by 2029, with a CAGR of 7.5%. The anticipated growth in this period could be linked to universal health strategies focused on cardiovascular health, increase in accessibility to reperfusion treatment options, RNA treatments for heart diseases, patient-centric care strategies, attention on microvascular malfunction, and the implementation of bioelectronic medicine. Key market trends predicted for this period incorporate improvements in imaging techniques related to the cardiovascular field, advancements in cardiac surgery methodologies, progress in telemedicine, the application of artificial intelligence in diagnosing, the invention of digital biomarkers for risk assessment, application of blockchain for securing healthcare data, utilization of AI in drug discovery, and technological innovations in cardiac rehabilitation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12164&type=smp

Which Key Companies Are Shaping the Future of the Myocardial Infarction Market?

Major companies operating in the myocardial infarction market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS

Which Factors Are Driving Demand in the Myocardial Infarction Industry?

The growth of the myocardial infarction market is forecasted to surge due to a rising number of smokers. A smoker is defined as an individual who uses cigarettes, cigars, or pipes. The chemicals contained in cigarette smoke cause the blood to thicken and clot in veins and arteries, leading to myocardial infarction by blocking them. For example, in September 2023, the UK’s Office for National Statistics revealed that the highest percentage of current smokers fell within the 25 to 34 year age bracket, with around 1.4 million or 16.3% individuals falling in this category in 2022. This percentage saw an increase from the previous year, with the same age group showing a prevalence of 15.8%, approximately 1.3 million people. Hence, the ongoing increase in the number of smokers is contributing to the expansion of the myocardial infarction market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12164&type=smp

How Is the Myocardial Infarction Market Segmented by Several Divisions?

The myocardial infarction market covered in this report is segmented –

1) By Drug Class: Antiplatelet Agents, Glycoprotein IIb Or IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin-Receptor Blockers, Analgesics, Thrombolytics

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor

2) By Glycoprotein IIb Or IIIa Inhibitors: Abciximab, Eptifibatide, Tirofiban

3) By Antithrombotic Agents: Heparins, Direct Oral Anticoagulants (DOACs)

4) By Beta-Adrenergic Blockers: Metoprolol, Carvedilol

5) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate

6) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Lisinopril, Enalapril

7) By Angiotensin-Receptor Blockers: Losartan, Valsartan

8) By Analgesics: Morphine, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

9) By Thrombolytics: Alteplase, Reteplase

What are the Emerging Market Trends Driving the Growth of the Myocardial Infarction Industry?

Leading firms in the myocardial infarction market are emphasizing on the creation of innovative drugs, such as anti-inflammatory medications, to cater to specific treatments for cardiovascular inflammation and establish a competitive advantage. These drugs work by reducing inflammation, thus lessening discomfort and swelling by addressing the body’s immune response. For example, in June 2023, Agepha Pharma, a medical product manufacturing company based in Slovakia, got FDA approval for its drug, Lodoco (colchicine), which is the first of its kind to direct its action towards the root cause of atherosclerotic cardiovascular disease. This anti-inflammatory medication aims to decrease the risk of heart attack, stroke, coronary revascularization, and cardiovascular mortality in adults. It can function independently or along with medications to lower cholesterol levels. In a clinical trial, Lodoco, a restructured formulation of low-dose colchicine, showed a drop of 31% in the total risk of cardiovascular death, heart attack, stroke, or coronary revascularization.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report

Which Regions Are Driving Growth in the Myocardial Infarction Market?

North America was the largest region in the myocardial infarction market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12164

This Report Delivers Insight On:

1. How big is the myocardial infarction market, and how is it changing globally?

2. Who are the major companies in the myocardial infarction market, and how are they performing?

3. What are the key opportunities and risks in the myocardial infarction market right now?

4. Which products or customer segments are growing the most in the myocardial infarction market?

5. What factors are helping or slowing down the growth of the myocardial infarction market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model